Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Characterization of urinary bile acids in a pediatric BRIC-1 patient: effect of rifampicin treatment.

Clinica chimica acta; international journal of clinical chemistry - 16 Aug 2012

Mizuochi Tatsuki, Kimura Akihiko, Tanaka Atsushi, Muto Akina, Nittono Hiroshi, Seki Yoshitaka, Takahashi Tomoyuki, Kurosawa Takao, Kage Masayoshi, Takikawa Hajime, Matsuishi Toyojiro

Abstract excerpt

BACKGROUND: Benign recurrent intrahepatic cholestasis type 1 (BRIC-1), a rare autosomal recessive disorder characterized by recurrent episodes of jaundice and pruritus, is caused by mutations in the ATP8B1 gene. Rifampicin has been reported to be an effective treatment of jaundice and pruritus in patients with BRIC. Proposed mechanisms of effect for rifampicin include enhancement of multidrug-resistance protein 2...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenosine Triphosphatases
Share to Bile Acids and Salts

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cholestasis

Share to Cholestasis, Intrahepatic

Share to Hydroxylation

Share to Mutation

Share to Rifampin

Source

Identifiers

PMID: 22525741
DOI: 10.1016/j.cca.2012.04.011

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Characterization of urinary bile acids in a pediatric BRIC-1 patient: effect of rifampicin treatment.PMID 22525741Read ↗

A Rare Case of Benign Recurrent Intrahepatic Cholestasis Initially Diagnosed in Middle-age.Semantic proximity Read ↗

Gradual improvement of liver function after administration of ursodeoxycholic acid in an infant with a novel ABCB11 gene mutation with phenotypic continuum between BRIC2 and PFIC2.Semantic proximity Read ↗

A novel homozygous mutation in the USP53 gene as the cause of benign recurrent intrahepatic cholestasis in children: a case report.Semantic proximity Read ↗

New paradigms of USP53 disease: normal GGT cholestasis, BRIC, cholangiopathy, and responsiveness to rifampicin.Semantic proximity Read ↗

Liver disease associated with canalicular transport defects: current and future therapies.Semantic proximity Read ↗

Two novel ATP8B1 mutations involved in progressive familial intrahepatic cholestasis type 1 that is ameliorated by rifampicin: A case report.Semantic proximity Read ↗

Successful treatment with colestimide for a bout of cholestasis in a Japanese patient with benign recurrent intrahepatic cholestasis caused by ATP8B1 mutation.Semantic proximity Read ↗

A patient with novel ABCB11 gene mutations with phenotypic transition between BRIC2 and PFIC2.Semantic proximity Read ↗

CYP3A4 Induction by Rifampin: An Alternative Pathway for Vitamin D Inactivation in Patients With CYP24A1 Mutations.Semantic proximity Read ↗

Characterization and treatment of persistent hepatocellular secretory failure.Semantic proximity Read ↗

Roles of rifampicin in drug-drug interactions: underlying molecular mechanisms involving the nuclear pregnane X receptorSemantic proximity Read ↗

OATP1B1 polymorphism is a major determinant of serum bilirubin level but not associated with rifampicin-mediated bilirubin elevation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.